Printed From BioPortfolio.com
Seattle Genetics Enters Two New Collaborations to Evaluating SGN-LIV1A in Triple Negative Breast Cancer
10:40 EDT 11 Oct 2017 | Speciality Pharma Journal
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ: SGEN) today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer (TNBC). SGN-LIV1A is an investigational antibody-drug conjugate (ADC) that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, ovarian, and cervical cancers. The …
Original Article: Seattle Genetics Enters Two New Collaborations to Evaluating SGN-LIV1A in Triple Negative Breast Cancer
